$28.14
3.03% today
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US19459J1043
Symbol
COLL

Collegium Pharmaceutical, Inc. Stock price

$28.14
+0.10 0.36% 1M
-13.72 32.78% 6M
-0.51 1.78% YTD
-11.16 28.40% 1Y
+8.90 46.26% 3Y
+10.58 60.25% 5Y
+15.85 128.97% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.88 3.03%
ISIN
US19459J1043
Symbol
COLL
Sector
Industry

Key metrics

Market capitalization $913.71m
Enterprise Value $1.71b
P/E (TTM) P/E ratio 15.71
EV/FCF (TTM) EV/FCF 8.39
EV/Sales (TTM) EV/Sales 2.70
P/S ratio (TTM) P/S ratio 1.45
P/B ratio (TTM) P/B ratio 3.99
Revenue growth (TTM) Revenue growth 11.41%
Revenue (TTM) Revenue $631.45m
EBIT (operating result TTM) EBIT $191.31m
Free Cash Flow (TTM) Free Cash Flow $203.33m
Cash position $187.76m
EPS (TTM) EPS $1.85
P/E forward 13.89
P/S forward 1.23
EV/Sales forward 2.30
Short interest 20.86%
Show more

Is Collegium Pharmaceutical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Collegium Pharmaceutical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Collegium Pharmaceutical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
631 631
11% 11%
100%
- Direct Costs 254 254
6% 6%
40%
377 377
16% 16%
60%
- Selling and Administrative Expenses 17 17
887% 887%
3%
- Research and Development Expense - -
-
-
360 360
11% 11%
57%
- Depreciation and Amortization 169 169
14% 14%
27%
EBIT (Operating Income) EBIT 191 191
9% 9%
30%
Net Profit 69 69
44% 44%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Collegium Pharmaceutical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Collegium Pharmaceutical, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025.
Neutral
GlobeNewsWire
8 days ago
STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, being held in Austin, TX, from April 3-6, 2025.
Neutral
GlobeNewsWire
18 days ago
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman  and Gwen A. Melincoff, Board Member to Retire from Board –
More Collegium Pharmaceutical, Inc. News

Company Profile

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

Head office United States
CEO Vikram Karnani
Employees 357
Founded 2002
Website www.collegiumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today